Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MannKind Corp MNKD

Healthcare Biotechnology
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the... see more

Recent & Breaking News (NDAQ:MNKD)

MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 1, 2022

MannKind Corporation Reports 2022 Second Quarter Financial Results

GlobeNewswire August 9, 2022

MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022

GlobeNewswire August 2, 2022

MannKind Corporation to Participate in the BTIG Biotechnology Conference

GlobeNewswire August 1, 2022

Mannkind to Host Product Theater and Booth at the American Diabetes Association's 82nd Scientific Sessions in New Orleans, June 3-7

GlobeNewswire June 3, 2022

MannKind's Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI(TM)

GlobeNewswire May 24, 2022

MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell

GlobeNewswire May 19, 2022

MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma

GlobeNewswire May 17, 2022

MannKind Corporation Participating at Upcoming Conferences

GlobeNewswire May 9, 2022

MannKind Corporation Reports 2022 First Quarter Financial Results

GlobeNewswire May 5, 2022

MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022

GlobeNewswire April 28, 2022

MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30

GlobeNewswire April 27, 2022

MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference

GlobeNewswire March 28, 2022

MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit

GlobeNewswire March 22, 2022

MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire March 8, 2022

MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results

GlobeNewswire February 24, 2022

Update on Tyvaso DPI(TM) New Drug Application

GlobeNewswire February 24, 2022

MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022

GlobeNewswire February 21, 2022

MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference

GlobeNewswire February 10, 2022

MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference

GlobeNewswire January 5, 2022